去氨加压素给药与蛛网膜下腔出血后再出血:一项观察性前瞻性数据库分析
基于哥伦比亚大学蛛网膜下腔出血结局项目1996年8月至2015年7月纳入的1639例患者,比较接受与未接受去氨加压素(DDAVP)治疗者的再出血率。校正抗血小板药物使用及已知预测因素后,DDAVP治疗与再出血风险降低45%相关(校正OR 0.55,95%CI 0.27-0.97)。DDAVP与低钠血症发生率升高相关,但与血栓事件或迟发性脑缺血无关。
要点
- 1639例SAH患者中12%接受DDAVP治疗,主要指征为疑似抗血小板药物暴露。
- 总体再出血发生率9%,DDAVP治疗组1%,未治疗组8%。
- 校正后DDAVP与再出血风险降低45%相关(校正OR 0.55,95%CI 0.27-0.97)。
核心结论
- 在SAH患者中,DDAVP治疗与较低的再出血风险相关。
- 这些发现支持进一步研究DDAVP作为SAH患者内科止血一线治疗。
研究设计与样本
- 观察性队列研究,纳入哥伦比亚大学SAH结局项目1996年8月至2015年7月期间入组的患者。
主要发现
- 1639例SAH患者中12%接受DDAVP治疗,主要治疗指征为疑似抗血小板药物暴露。
- 总体再出血发生率为9%,DDAVP治疗组为1%,未治疗组为8%。
- 校正抗血小板药物使用及已知预测因素后,DDAVP治疗与再出血风险降低45%相关(校正OR 0.55,95%CI 0.27-0.97)。
- DDAVP与低钠血症发生率升高相关,但与血栓事件或迟发性脑缺血无关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Rebleeding remains a frequent and catastrophic event leading to poor outcome after subarachnoid hemorrhage (SAH). Reduced platelet function after the initial bleed is associated with higher risk of early rebleeding. Desmopressin (DDAVP) is a well-known hemostatic agent, and recent guidelines already suggest its use in individuals exposed to antiplatelet drugs. The authors hypothesized that DDAVP administration in patients with SAH at admission would be associated with lower risks of rebleeding. METHODS: The authors performed an observational cohort study of patients enrolled in the Columbia University SAH Outcome Project between August 1996 and July 2015. The authors compared the rate of rebleeding between patients who were and those who were not treated with DDAVP. After adjustment for known predictors, logistic regression was used to measure the association between treatment with DDAVP and risks of rebleeding. RESULTS: Among 1639 patients with SAH, 12% were treated with DDAVP. The main indication for treatment was suspected exposure to an antiplatelet agent. The overall incidence of rebleeding was 9% (1% among patients treated with DDAVP compared with 8% among those not treated). After adjustment for antiplatelet use and known predictors, treatment with DDAVP was associated with a 45% reduction in the risks of rebleeding (adjusted OR 0.55, 95% CI 0.27-0.97). DDAVP was associated with a higher incidence of hyponatremia but not with thrombotic events or delayed cerebral ischemia. CONCLUSIONS: Treatment with DDAVP was associated with a lower risk of rebleeding among patients with SAH. These findings support further study of DDAVP as first-line therapy for medical hemostasis in patients with SAH.
引用
- Francoeur CL, Roh D, Schmidt JM, et al. Desmopressin administration and rebleeding in subarachnoid hemorrhage: analysis of an observational prospective database. J Neurosurg. 2018. PMID: 29393750. doi:10.3171/2017.7.JNS17990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。